Key result
Catastrophic antiphospholipid syndrome causes fatal recurrent intracardiac thrombus and pulmonary thromboembolism in a pediatric patient.
Why the study?
Intracardiac thrombus is a life-threatening but treatable complication in patients with antiphospholipid syndrome, and catastrophic APS is a rare severe form with limited reported cases, especially in young patients.
Case Report (n=1)
Emphasizes poor prognosis in pediatric catastrophic antiphospholipid syndrome despite treatment; extends reported age range and leaves optimal management open.
Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia characterized by venous and/or arterial thromboses, pregnancy morbidity (predominantly repeated fetal losses), and the presence of phospholipid antibodies. The estimated annual incidence of APS is 5 new cases per 100,000 people. The most common thrombotic events in patients with APS in order of frequency are stroke, transient ischemic attack, deep vein thrombosis, and pulmonary embolism. Patients with APS may develop an intracardiac thrombus, which is a life-threatening complication with a high risk of increased morbidity and mortality; however, it is treatable by surgical removal, extensive anticoagulant administration, and prevention of other complications. Catastrophic APS, which is a rare and severe condition diagnosed based on rapidly progressive thromboembolic events involving three or more organs, systems, or tissues, occurs in less than 1% of all patients with APS. We herein report an autopsy case of catastrophic APS in a 12-year-old Thai boy with multiple thromboembolic events including intracardiac thrombus formation with a positive lupus anticoagulant test result. To the best of our knowledge, this is the youngest reported patient with APS to date.
No takes yet. Share an insight, caveat, or question.
Waisayarat et al. (2019) conducted a case report in Catastrophic antiphospholipid syndrome (CAPS) (n=1). Surgical thrombus removal and medical therapy (anticoagulation, immunosuppressants) was evaluated. A 12-year-old boy with catastrophic antiphospholipid syndrome developed a recurrent intracardiac thrombus and pulmonary thromboembolism despite extensive treatment, ultimately resulting in death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: